Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Norethisterone enantate + estradiol valerate is a combined injectable contraceptive containing two hormones: norethisterone enantate, a synthetic progestogen (progestin), and estradiol valerate, a synthetic estrogen. Administered as an intramuscular depot injection once monthly, it provides effective contraception by suppressing ovulation and altering the endometrium and cervical mucus to prevent pregnancy. The combination is also used in hormone replacement therapy for menopausal symptoms and prevention of osteoporosis in postmenopausal women. After injection, both esters are hydrolyzed to their active forms—norethisterone and estradiol—which act as agonists at the progesterone receptor and estrogen receptor, respectively[1][4][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on norethisterone enantate + estradiol valerate.